Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

被引：602

作者：

Khan, Nagma ^{[1
]}

Jeffers, Michael ^{[3
]}

Kumar, Sampath ^{[3
]}

Hackett, Craig ^{[3
]}

Boldog, Ferenc ^{[3
]}

Khramtsov, Nicholai ^{[3
]}

Qian, Xiaozhong ^{[3
]}

Mills, Evan ^{[3
]}

Berghs, Stanny C. ^{[3
]}

Carey, Nessa ^{[1
]}

Finn, Paul W. ^{[1
]}

Collins, Laura S. ^{[1
]}

Tumber, Anthony ^{[1
]}

Ritchie, James W. ^{[1
]}

Jensen, Peter Buhl ^{[2
]}

Lichenstein, Henri S. ^{[3
]}

Sehested, Maxwell ^{[2
]}

机构：

[1] Topotarget UK Ltd, Abingdon OX14 4RY, Oxon, England

[2] Topotarget A S, DK-2100 Copenhagen, Denmark

[3] CuraGen Corp, Branford, CT 06405 USA

来源：

BIOCHEMICAL JOURNAL | 2008年 / 409卷

关键词：

deacetylation; histone deacetylase (HDAC); histone deacetylase isoforms (HDAC isoforms); small-molecule inhibitors; tubulin;

D O I：

10.1042/BJ20070779

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The human HDAC (histone deacetylase) family, a well-validated anticancer target, plays a key role in the control of gene expression through regulation of transcription. While HDACs can be subdivided into three main classes, the class 1, class 11 and class III HDACs (sirtuins), it is presently unclear whether inhibiting multiple HDACs using pan-HDAC inhibitors, or targeting specific isoforms that show aberrant levels in tumours, will prove more effective as an anticancer strategy in the clinic. To address the above issues, we have tested a number of clinically relevant HDACis (HDAC inhibitors) against a panel of rhHDAC (recombinant human HDAC) isoforms. Eight rhHDACs were expressed using a baculoviral system, and a Fluor de Lys (TM) (Biomol International) HDAC assay was optimized for each purified isoform. The potency and selectivity of ten HDACs on class I isoforms (rhHDAC], rhHDAC2, rhHDAC3 and rhHDAC8) and class 11 HDAC isoforms (rhHDAC4, rhHDAC6, rhHDAC7 and rhHDAC9) was determined. MS-275 was HDAC1-selective, MGCDO103 was HDAC1- and HDAC2-selective, apicidin was HDAC2- and HDAC3-selective and valproic acid was a specific inhibitor of class I HDACs. The hydroxamic acid-derived compounds (trichostatin A, NVP-LAQ824, panobinostat, ITF2357, vorinostat and belinostat) were potent pan-HDAC inhibitors. The growth-inhibitory effect of the HDACis on HeLa cells showed that both pan-HDAC and class-I-specific inhibitors inhibited cell growth. The results also showed that both pan-HDAC and class-I-specific inhibitor treatment resulted in increased acetylation of histones, but only pan-HDAC inhibitor treatment resulted in increased tubulin acetylation, which is in agreement with their activity towards the HDAC6 isoform.

引用

页码：581 / 589

页数：9

共 51 条

[1] Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors [J].